Trillium Therapeutics Inc (TRIL.CA) Stock Price, Quote, News and Overview
TSX:TRIL - Toronto Stock Exchange -
TRIL.CA Quote, Performance and Key Statistics
TSX:TRIL (11/19/2021, 7:00:00 PM)
23.33
+0.11 (+0.47%)
The current stock price of TRIL.CA is 23.33 null. In the past month the price increased by 5.33%.
TRIL.CA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 261.54M | ||
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 188.23M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 185.09M | ||
| TH.CA | THERATECHNOLOGIES INC | N/A | 121.39M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 89.95M | ||
| ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 82.42M | ||
| MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 78.27M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 25.45 | 76.72M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | 48.5 | 65.22M | ||
| MDCX.CA | MEDICUS PHARMA LTD | N/A | 61.74M | ||
| SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 52.45M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 51.96M |
Related stock screener links
About TRIL.CA
Company Profile
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. The company is headquartered in Mississauga, Ontario and currently employs 33 full-time employees. The company went IPO on 2005-01-11. The firm is engaged in developing therapies for the treatment of cancer. The firm is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). The company focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.
Company Info
Trillium Therapeutics Inc
2488 Dunwin Drive
Mississauga ONTARIO 02140 CA
CEO: Jan Skvarka
Employees: 33
Company Website: http://www.trilliumtherapeutics.com/
Phone: 14165950627.0
Trillium Therapeutics Inc / TRIL.CA FAQ
What is the stock price of Trillium Therapeutics Inc today?
The current stock price of TRIL.CA is 23.33 null. The price increased by 0.47% in the last trading session.
What is the ticker symbol for Trillium Therapeutics Inc stock?
The exchange symbol of Trillium Therapeutics Inc is TRIL and it is listed on the Toronto Stock Exchange exchange.
On which exchange is TRIL.CA stock listed?
TRIL.CA stock is listed on the Toronto Stock Exchange exchange.
What is the price forecast or stock price prediction for Trillium Therapeutics Inc stock?
10 analysts have analysed TRIL.CA and the average price target is 18.87 null. This implies a price decrease of -19.12% is expected in the next year compared to the current price of 23.33. Check the Trillium Therapeutics Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Trillium Therapeutics Inc worth?
Trillium Therapeutics Inc (TRIL.CA) has a market capitalization of 2.45B null. This makes TRIL.CA a Mid Cap stock.
How many employees does Trillium Therapeutics Inc have?
Trillium Therapeutics Inc (TRIL.CA) currently has 33 employees.
What are the support and resistance levels for Trillium Therapeutics Inc (TRIL.CA) stock?
Trillium Therapeutics Inc (TRIL.CA) has a support level at 22.66. Check the full technical report for a detailed analysis of TRIL.CA support and resistance levels.
Is Trillium Therapeutics Inc (TRIL.CA) expected to grow?
The Revenue of Trillium Therapeutics Inc (TRIL.CA) is expected to decline by -96.9% in the next year. Check the estimates tab for more information on the TRIL.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Trillium Therapeutics Inc (TRIL.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TRIL.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TRIL.CA, evaluating the profitability, health, valuation and growth aspects
- Trillium Therapeutics Inc (TRIL.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Trillium Therapeutics Inc (TRIL.CA) Sales and EPS estimates to see what analysts future expectations are.
- Trillium Therapeutics Inc (TRIL.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Trillium Therapeutics Inc (TRIL.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- Trillium Therapeutics Inc (TRIL.CA) Stock Chart to make your own analysis
- Trillium Therapeutics Inc (TRIL.CA) Latest news and press-releases to stay up to date.
Does Trillium Therapeutics Inc (TRIL.CA) stock pay dividends?
TRIL.CA does not pay a dividend.
What is the Price/Earnings (PE) ratio of Trillium Therapeutics Inc (TRIL.CA)?
Trillium Therapeutics Inc (TRIL.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.01).
TRIL.CA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TRIL.CA. When comparing the yearly performance of all stocks, TRIL.CA is one of the better performing stocks in the market, outperforming 93.21% of all stocks.
TRIL.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TRIL.CA. While TRIL.CA has a great health rating, there are worries on its profitability.
TRIL.CA Financial Highlights
Over the last trailing twelve months TRIL.CA reported a non-GAAP Earnings per Share(EPS) of -1.01. The EPS increased by 52.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -139737.5% | ||
| ROA | -21.06% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
TRIL.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to TRIL.CA. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -9.05% and a revenue growth -96.9% for TRIL.CA